Cargando…

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review

BACKGROUND: Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Wilde, Arno, van Buchem, Marieke M., Otten, René H. J., Bouwman, Femke, Stephens, Andrew, Barkhof, Frederik, Scheltens, Philip, van der Flier, Wiesje M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064628/ https://www.ncbi.nlm.nih.gov/pubmed/30055660 http://dx.doi.org/10.1186/s13195-018-0398-3

Ejemplares similares

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline
por: Verfaillie, Sander C.J., et al.
Publicado: (2016)

Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
por: Caprioglio, Camilla, et al.
Publicado: (2023)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia
por: van Straaten, Elisabeth CW, et al.
Publicado: (2012)

Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
por: van der Schaar, Jetske, et al.
Publicado: (2022)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
por: den Haan, Jurre, et al.
Publicado: (2019)

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease
por: van Maurik, Ingrid S, et al.
Publicado: (2019)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Survival in memory clinic cohort is short, even in young-onset dementia
por: Rhodius-Meester, Hanneke Frederica Maria, et al.
Publicado: (2019)

A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure
por: Ott, Brian R., et al.
Publicado: (2016)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial
por: Altomare, Daniele, et al.
Publicado: (2023)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Multitracer model for staging cortical amyloid deposition using PET imaging
por: Collij, Lyduine E., et al.
Publicado: (2020)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure
por: Lingler, Jennifer H., et al.
Publicado: (2018)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Small vessel disease lesion type and brain atrophy: The role of co‐occurring amyloid
por: Heinen, Rutger, et al.
Publicado: (2020)

Amyloid deposition in semantic dementia: a positron emission tomography study
por: Brown, Eric E., et al.
Publicado: (2016)

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
por: ten Kate, Mara, et al.
Publicado: (2018)

Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis
por: Harper, Lorna, et al.
Publicado: (2017)

A clinical-radiological framework of the right temporal variant of frontotemporal dementia
por: Ulugut Erkoyun, Hulya, et al.
Publicado: (2020)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline
por: van Maurik, Ingrid S., et al.
Publicado: (2020)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jpsoei4r9sfrlvh1uugil0vdl1